anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Information associated with a person is securely collected, generated, and provisioned. At least one computing device secures at least some of received information (secured information) and stores the secured information on a distributed ledger system. A request to access the secured information is received. If the requesting device(s) do not have authorization to access the secured information, a virtual representation of the person with the request for authorization to access the secured information. The virtual representation of the person receives via the VR/AR environment from the person, the authorization, and the computing device(s) automatically provide, in response to receiving the authorization, the at least one other computing device with access to the secured information. Alternatively, where the at least one other computing device has authorization to access the secured information, the at least one computing device automatically provides the at least one other computing device with access to the secured information.
This clinical trial will uncover new mechanisms of inter-individual responses to endogenous and exogenous glucagon-like peptide-1 (GLP-1) in Hispanics/Latinos (H/Ls) with prediabetes. The results move the management of prediabetes, type 2 diabetes mellitus (T2DM), and relevant metabolic diseases to a more individualized approach in an understudied and at-risk population. Few options exist for prediabetes treatment, and the current pharmaceutical management of T2DM does not predict drug treatment failures, nor differences in individual treatment responses and adverse effects. A precise, genetics-based approach will provide superior therapeutic management for patients. GLP-1-based therapies reduce blood glucose, promote weight loss, decrease cardiovascular events, and improve renal function. Prior genetic studies, most done in Caucasians, identified associations between genetic variants and decreased GLP-1-induced insulin secretion, in an effort to guide individualized treatment. However, these associations do not provide a clear mechanistic relationship between genotype and phenotype. Transcriptomic analyses will uncover many of these mechanisms. Here, we propose to 1) test the association of single nucleotide polymorphisms (SNPs) that regulate expression (eQTLs) of 11 candidate genes in a range of relevant metabolic tissues with differential GLP-1 response, 2) perform RNA sequencing before and after treatment to identify eQTLs in blood that predict response to GLP-1 therapy and develop risk-based prediction models in H/Ls, and 3) determine the effects of genetic regulation of candidate genes and newly discovered eQTLs phenome-wide in a large existing biobank, BioVU. For aims 1 and 2, responses will be measured in 300 study subjects with prediabetes recruited from an established Mexican-American cohort via the oral minimal model method, before and after GLP-1 therapy, quantifying GLP-1 hormone efficacy and GLP-1-induced pancreatic beta cell insulin release and peripheral insulin sensitivity. Procedures include serial measurements of plasma glucose, insulin, C-peptide, and GLP-1, and peripheral blood collection for RNA sequencing. Our central hypotheses are: (1) metabolic tissue-based eQTLs of GLP-1-associated genes will be associated with physiological response to endogenous and exogenous GLP-1,(2) identification of eQTLs associated with GLP-1 treatment-induced changes in whole blood will identify new gene targets, and (3) this data will lead to the creation of eQTL-based prediction models for related diseases. The study is innovative because it uses a novel combination of eQTL analysis and oral minimal model to assess GLP-1 response, examines a population highly underrepresented in pharmacogenomic studies, and utilizes novel statistical methods and applications to study gene expression. The significance of this newly acquired mechanistic information will ultimately guide precision therapeutic regimens for diabetes prevention and treatment, weight loss, cardiovascular risk reduction, and related metabolic complications in an understudied population.
INTRODUCTION: As people living with HIV (PLHIV) are experiencing longer survival, the co-occurrence of HIV and non-communicable diseases has become a public health priority. In response to this emerging challenge, we aimed to characterise the spatial structure of convergence of chronic health conditions in an HIV hyperendemic community in KwaZulu-Natal, South Africa.
METHODS: In this cross-sectional study, we used data from a comprehensive population-based disease survey conducted in KwaZulu-Natal, South Africa, which collected data on HIV, diabetes and hypertension. We implemented a novel health needs scale to categorise participants as: diagnosed and well-controlled (Needs Score 1), diagnosed and suboptimally controlled (Score 2), diagnosed but not engaged in care (Score 3) or undiagnosed and uncontrolled (Score 4). Scores 2-4 were indicative of unmet health needs. We explored the geospatial structure of unmet health needs using different spatial clustering methods.
RESULTS: The analytical sample comprised 18 041 individuals. We observed a similar spatial structure for HIV among those with combined needs Score 2-3 (diagnosed but uncontrolled) and Score 4 (undiagnosed and uncontrolled), with most PLHIV with unmet needs clustered in the southern urban and peri-urban areas. Conversely, a high prevalence of need Scores 2 and 3 for diabetes and hypertension was mostly distributed in the more rural central and northern part of the surveillance area. A high prevalence of need Score 4 for diabetes and hypertension was mostly distributed in the rural southern part of the surveillance area. Multivariate clustering analysis revealed a significant overlap of all three diseases in individuals with undiagnosed and uncontrolled diseases (unmet needs Score 4) in the southern part of the catchment area.
CONCLUSIONS: In an HIV hyperendemic community in South Africa, areas with the highest needs for PLHIV with undiagnosed and uncontrolled disease are also areas with the highest burden of unmet needs for other chronic health conditions, such as diabetes and hypertension. Our study has revealed remarkable differences in the distribution of health needs across the rural to urban continuum even within this relatively small study site. The identification and prioritisation of geographically clustered vulnerable communities with unmet health needs for both HIV and non-communicable diseases provide a basis for policy and implementation strategies to target communities with the highest health needs.
The invention discloses an application of osteopetrosis-related transmembrane protein in a medicine for treatment or prevention of EV71 infection. The application comprises the following steps: firstly, expressing Ostml protein by an insect baculovirus expression system in an insect cell (SF9); purifying the Ostml protein by a nickel column affinity chromatography method; and finally, validating the antiviral effect of the Ostml protein in EV71-infected malignant rhabdomyosarcoma cells (RD cell). An experiment result proves that the purified Ostml protein is capable of inhibiting EV71 virus replication in mRNA level and protein level at certain concentration. The anti-EV71 virus effect of the osteopetrosis-related transmembrane protein (Ostml) is evaluated from protein purification and nucleus molecular level; a foundation is laid for further development and application. The protein is capable of directly inhibiting EV71 virus replication at proper concentration, is obvious in effect and free of a side effect on the cell, and simple and convenient to use. The medicine has the prospect that the medicine can be developed into an anti-EV71 virus effective medicine for clinical application.
INTRODUCTION: Severe recurrent aphthous stomatitis (RAS) represents a therapeutic challenge because of its impact on the patient's quality of life. Additionally, no approved systemic therapies are available. Roflumilast, a phosphodiesterase-4 inhibitor, has shown promise in other inflammatory dermatological conditions. This study aimed to assess the characteristics, effectiveness, and safety of roflumilast in treating RAS in routine clinical practice.
METHODS: This is a single cohort ambispective observational study conducted in five Spanish centers. Twenty-two patients with RAS treated with roflumilast participated. Data collection included demographic, clinical, and outcome variables. Statistical analysis compared the outcomes of 12 weeks of roflumilast treatment with a similar prior period without treatment.
RESULTS: During treatment with roflumilast, a significant reduction in flare-ups (88%) and oral ulcers (94%) was observed compared to the untreated period. A reduction in pain (66%) and ulcer duration (63%) was observed. Adverse effects (AEs) occurred in 13 patients, predominantly headache and gastrointestinal disturbances. Most of these were self-limiting or manageable with dose adjustment. Treatment was withdrawn in three cases, mainly because of AEs.
CONCLUSIONS: This study suggests that roflumilast may effectively treat RAS by reducing the number of flare-ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology.
The invention discloses an AGNM composition, and a preparation and application thereof. The AGNM composition consists of astaxanthin, gamma-aminobutyric acid and beta-nicotinamide mononucleotide. The preparation of the AGNM composition is prepared by adding auxiliary materials into the ASBDV composition to prepare tablets, oral liquid, capsules, granules, powder, pills, injections, films or patches. The application is the application in the products for preventing/improving/treating insomnia and related diseases. The AGNM composition has obvious improvement effects on stress, anxiety and insomnia symptoms; the cognitive function (language fluency and execution capacity) can be obviously improved; improving skin texture and resisting aging, and has good effects of keeping moisture, removing wrinkle, resolving macula, relieving skin greasiness, and maintaining skin elasticity. The AGNM composition can effectively stimulate the gene activity of anti-senility enzyme and has potential preventing and treating effect on diseases related to senility (Alzheimer's disease, Parkinson, vascular dementia and the like).
Image interpretation errors can occur with LOCAMETZ PET. Negative imaging does not rule out the presence of prostate cancer and a positive imaging does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes, such as Paget’s disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Imaging Prior to Initial Definitive or Suspected Recurrence Therapy

The performance of LOCAMETZ for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of LOCAMETZ for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score [see Clinical Studies (14.1, 14.2)].

Imaging to Select Patients for Lutetium Lu 177 Vipivotide Tetraxetan Therapy

The interpretation of LOCAMETZ PET may differ depending on imaging readers [see Dosage and Administration (2.8)]. LOCAMETZ PET interpretations to select patients for lutetium Lu 177 vipivotide tetraxetan therapy may be more consistent when judging gallium Ga 68 gozetotide uptake in any one tumor lesion compared to judging uptake for all lesions larger than size criteria [see Clinical Studies (14.3)]. Multidisciplinary consultation to select patients for lutetium Lu 177 vipivotide tetraxetan therapy is recommended, particularly for LOCAMETZ imaging that a single reader finds borderline or difficult to interpret, or when patient eligibility hinges only on judgment of gallium Ga 68 gozetotide uptake for all lesions larger than size criteria.
The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI\< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
Subjects in this study arm received a dry sterile dressing (Primapore®, Smith \& Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
The invention comprises sulphonyl ureas of the formula R1.SO2.NH.CO.NH.R2 wherein R1 is an amino group disubstituted by aliphatic hydrocarbon radicals, the carbon chains of which may optionally be interrupted by an oxygen, nitrogen or sulphur atom and R2 is a hydrocarbon or oxahydrocarbon radical of aliphatic character, optionally substituted by a phenyl radical which may itself bear C1-3 alkyl, alkoxy or alkylthio or halo or trifluoromethyl substituents and salts of these compounds with bases, such as the alkali-metal or alkaline earth metal salts.  Suitable aliphatic hydrocarbon radicals include alkyl, alkenyl, alkylene, cycloalkyl, cycloalkenyl, cycloalkyl-alkyl and cycloalkenyl-alkyl radicals, preferred compounds being ureas of the formula R3(R4)N.SO2.NH.CO.NH.R5 wherein R3 and R4 represent C1-4 alkyl radicals or together form an alkylene or oxa-alkylene radical of 4-8 carbon atoms and R5 is a C1-8 alkyl radical or a cycloalkyl or phenyl-ethyl radical.  The compounds are prepared by known methods for converting organic isocyanates into ureas such as reaction of a sulphonamide R1.SO2.NH2 with an isocyanate OCN.R2, preferably in an organic solvent and in the presence of an alkali-metal hydroxide or carbonate.  The products are used pharmaceutically.  Examples describe products wherein R1 is a piperidino-, morpholino-, pyrrolidino-, di-n-propylamino-, hexamethyleneimino- or 1,2,3,4-tetrahydro-isoquinolinogroup and R2 is an n-butyl-, ethyl-, cyclohexyl-, phenyl-ethyl-, 2 : 4-dimethyl-pentyl-(3)-, isobutyl- or benzylradical.  Pyrrolidino-, hexamethyleneimino- and 1,2,3,4-tetrahydro-isoquinolino-sulphonamides used as starting materials are made by the action of sulphamide on the corresponding heterocyclic base.  Pharmaceutical preparations for the treatment of diabetes comprise the above sulphonyl ureas in admixture or conjunction with a pharmaceutical carrier suitable for enterably (preferal oral) or parenteral administration.  The preparations suitably take the form of tablets, dragees, powders, suppositories, solutions, suspensions or emulsions.
PURPOSE: To obtain an emulsion of a raw organopolysiloxane rubber which is prepd. by emulsifying a raw organopolysiloxane rubber in water and is useful for a base material for cosmetics, a lustering agent, a lubricant, an antifoaming agent, a fiber treatment, an additive for a coating material, etc. CONSTITUTION: This emulsion comprises 100 pts.wt. raw organopolysiloxane rubber having a plasticity (according to JIS C 2123) of 0.75mm or higher at 25 deg.C, 1-100 pts.wt. emulsifier, and 3-80 pts.wt. water, is prepd. by emulsifying the rubber with the emulsifier in water, and has a rubber content of 11-95wt.%.
Bipolar disorder, also called manic-depressive illness, is a brain disorder that causes dramatic changes in a person's mood and energy. Bipolar disorder normally forms in late adolescence or early adulthood and requires treatment for the rest of a person's life. People with bipolar disorder undergo periods of extreme happiness and extreme sadness, known as episodes of mania and depression. Symptoms of mania can include increased energy, euphoric moods, mind racing, aggressive behavior, substance abuse, and poor decision making. Symptoms of depression can include persistent feelings of anxiety, guilt, or hopelessness; irregular sleep and appetite patterns; lethargy; disinterest in previously enjoyed activities; excessive irritability and restlessness; and inability to concentrate. Some people with bipolar disorder also become suicidal. Suicidal behaviors are more likely to occur at the onset of the illness, making it vital to recognize and treat the disorder early on. Current treatments include mood stabilizing medications and psychotherapy. This study will evaluate the effectiveness of two different mood stabilizing medications, lithium and valproate, in treating people with bipolar disorder and suicidal behavior.

Participants in this double-blind study will be randomly assigned to take one of two medications, either lithium or valproate. In the first 2 to 6 months, depending on clinical condition, participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine. Participants will attend regular visits to a psychiatrist or a psychologist at the Neuroscience Clinic. A blood sample will be taken at each visit to monitor medication blood levels. Participants will also undergo periodic routine laboratory and urine tests to assure their safety.

If the psychiatrist feels improvement has occurred by the end of the 2- to 6-month period, participants will be gradually taken off paroxetine and/or olanzapine over a 2-week period. They will then continue taking the assigned lithium or valproate for the remainder of the study. If the psychiatrist feels the condition has worsened, participants will be prescribed new medications as needed. These medications include other antidepressants (bupropion or venlafaxine) or other antimanic or antipsychotic drugs (perphenazine or haloperidol). Once these participants have achieved at least 2 weeks of normal moods, they will be gradually taken off all other prescribed medications and will remain taking the assigned lithium or valproate. Participants who do not achieve at least 2 weeks of normal moods will stop study participation but will still be offered clinical treatment. The remaining participants taking only lithium or valproate will continue their regular visits with a psychiatrist for the last 6 months of the study. The entire study will last 12 months.
FIELD: biotechnology.SUBSTANCE: immunogenic composition is described for the prevention of a disease or condition related toS. pneumoniae, containing glycoconjugate based onS. pneumoniaeserotype 22F. Glycoconjugate has molecular weight from 1000 KDa to 12,500 KDa and contains isolated capsule polysaccharideS. pneumoniaeserotype 22F and a protein carrier. Activated polysaccharide of serotype 22F has molecular weight from 70 KDa to 700 KDa. A ratio (wt./wt.) of polysaccharide to the protein carrier is from 0.4 to 1.2. The specified glycoconjugate of serotype 22F contains at least 0.7 mM of acetate per mM of capsule polysaccharide of serotype 22F. The specified glycoconjugate of serotype 22F is obtained using reducing amination, and an oxidation degree of activated polysaccharide of serotype 22F is from 12 to 20. The specified protein carrier is CRM197.EFFECT: invention expands the arsenal of immunogenic compositions for the prevention of a disease or condition related toS. pneumoniae.28 cl, 16 dwg, 25 tbl, 20 ex
From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
BACKGROUND: Venous thromboembolism (VTE) remains a persistent source of postoperative morbidity despite prevention and mitigation efforts. Cancer, surgery, and chemotherapy are known risk factors for VTE. Existing literature suggests that neoadjuvant therapy (NAT) may contribute to increased VTE risk in the postoperative period, but few authors specifically examine this relationship in distal pancreatic adenocarcinoma (PDAC). In this study, we analyze the association of NAT and postoperative VTE in patients who underwent distal pancreatectomy (DP) for PDAC.
PATIENTS AND METHODS: Using the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database, we analyzed the Procedure Targeted files for pancreatectomy from 2014 to 2020. Adults with PDAC who underwent DP were grouped by receipt of NAT. The primary outcome was the rate of deep venous thrombosis (DVT) and the secondary outcome was the rate of pulmonary embolism (PE). We performed univariate and multivariate logistic regression analysis to determine risk factors associated with postoperative DVT.
RESULTS: There were 4327 patients with PDAC who underwent DP. Of these, 1414 (32.7%) had NAT. Receipt of NAT was significantly associated with postoperative DVT requiring therapy (3.5% vs. 2.3%, p = 0.02), but was not associated with PE (p = 0.42). On MVA, NAT was associated with a 73% greater chance of developing postoperative DVT [odds ratio (OR) 1.73, 95% CI 1.18-2.55].
CONCLUSIONS: Patients who receive NAT prior to DP for PDAC are 73% more likely to develop postoperative DVT compared with upfront resection. As NAT becomes more commonplace, these high-risk patients should be prioritized for guideline-recommended extended duration prophylaxis.